Group One Trading’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-9,305
| Closed | -$17.2K | – | 7855 |
|
|
2026
Q1 | $11.2K | Buy |
9,305
+4,874
| +110% | +$5.93K | ﹤0.01% | 6317 |
|
|
2025
Q4 | $4.35K | Buy |
4,431
+1,600
| +57% | +$1.92K | ﹤0.01% | 7241 |
|
|
2025
Q3 | $3.57K | Buy |
+2,831
| New | +$3.05K | ﹤0.01% | 7698 |
|
|
2025
Q1 | – | Sell |
-8,728
| Closed | -$10.7K | – | 7815 |
|
|
2024
Q4 | $14.4K | Buy |
8,728
+6,611
| +312% | +$16.7K | ﹤0.01% | 5906 |
|
|
2024
Q3 | $7.41K | Buy |
+2,117
| New | +$8.24K | ﹤0.01% | 5731 |
|
|
2024
Q2 | – | Sell |
-1,050
| Closed | -$4.6K | – | 6944 |
|
|
2024
Q1 | $7.71K | Sell |
1,050
-15,639
| -94% | -$96.8K | ﹤0.01% | 6001 |
|
|
2023
Q4 | $62.4K | Buy |
16,689
+10,400
| +165% | +$24.5K | ﹤0.01% | 4891 |
|
|
2023
Q3 | $13.3K | Buy |
+6,289
| New | +$20.8K | ﹤0.01% | 6168 |
|
|
2023
Q1 | – | Sell |
-2,654
| Closed | -$16K | – | 7409 |
|
|
2022
Q4 | $26.8K | Buy |
2,654
+419
| +19% | +$7.87K | ﹤0.01% | 5428 |
|
|
2022
Q3 | $50K | Sell |
2,235
-9,201
| -80% | -$266K | ﹤0.01% | 5402 |
|
|
2022
Q2 | $283K | Buy |
11,436
+5,200
| +83% | +$143K | ﹤0.01% | 3960 |
|
|
2022
Q1 | $242K | Buy |
+6,236
| New | +$241K | ﹤0.01% | 4598 |
|
|
2021
Q3 | – | Sell |
-5,427
| Closed | -$426K | – | 8336 |
|
|
2021
Q2 | $471K | Buy |
+5,427
| New | +$437K | ﹤0.01% | 4281 |
|
|
2020
Q4 | – | Sell |
-1,691
| Closed | -$105K | – | 6637 |
|
|
2020
Q3 | $68K | Sell |
1,691
-5,373
| -76% | -$188K | ﹤0.01% | 4442 |
|
|
2020
Q2 | $242K | Sell |
7,064
-19,258
| -73% | -$574K | ﹤0.01% | 3227 |
|
|
2020
Q1 | $585K | Buy |
26,322
+23,730
| +916% | +$600K | ﹤0.01% | 1942 |
|
|
2019
Q4 | $51K | Buy |
2,592
+2,328
| +882% | +$37K | ﹤0.01% | 3994 |
|
|
2019
Q3 | $4K | Sell |
264
-1,200
| -82% | -$23K | ﹤0.01% | 4805 |
|
|
2019
Q2 | $30K | Sell |
1,464
-2,900
| -66% | -$52.3K | ﹤0.01% | 4020 |
|
|
2019
Q1 | $77K | Sell |
4,364
-3,361
| -44% | -$53.1K | ﹤0.01% | 3338 |
|
|
2018
Q4 | $99K | Buy |
+7,725
| New | +$108K | ﹤0.01% | 3157 |
|
|
2018
Q3 | – | Sell |
-23,312
| Closed | -$276K | – | 5307 |
|
|
2018
Q2 | $264K | Buy |
+23,312
| New | +$257K | ﹤0.01% | 2825 |
|
Other funds holding FATE
RG
JJ
Group One Trading's FATE Position: Q2 2026 in Review
Group One Trading sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 9,305 shares — an estimated $17.2K sold.
Group One Trading first reported a position in FATE in Q2 2018 and held it in 22 quarters. The position peaked at $585K in Q1 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.
- Group One Trading reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
- Group One Trading sold 9,305 Fate Therapeutics shares in Q2 2026, an estimated $17.2K.
- Group One Trading first reported a position in Fate Therapeutics in Q2 2018 and held it in 22 quarters.
- Group One Trading's Fate Therapeutics position peaked at $585K in Q1 2020.
- 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.